Furthermore, a novel EXO-T vaccine was developed which converted the exhausted T cells into tumor-specific effector CTL via the CD40L signaling pathway of CD4+ T cells to stimulate a more massive CTL anti-tumor response (159). This evidence concerns the gene CD4 and neoplasm.